Barbara J Brennan

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. doi Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin
    Barbara J Brennan
    Pharma Research and Early Development, Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    Clin Pharmacokinet 52:805-13. 2013
  2. pmc Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity
    Barbara J Brennan
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Br J Clin Pharmacol 75:497-506. 2013
  3. doi Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study
    Barbara J Brennan
    Hoffmann La Roche Inc, Nutley, New Jersey 07110, USA
    Clin Ther 34:1883-91. 2012
  4. doi The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C
    B J Brennan
    Roche, Nutley, NJ, USA
    Aliment Pharmacol Ther 35:1209-20. 2012
  5. ncbi Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease
    Barbara J Brennan
    Department of Pharmacy Practice, Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA
    J Am Pharm Assoc (2003) 44:604-10; quiz 610-1. 2004
  6. ncbi Effect of age and gender on the pharmacokinetics of R667, a novel agent for the treatment of emphysema, in healthy volunteers
    B Brennan
    Hoffmann La Roche, Nutley, NJ, USA
    J Pharm Pharm Sci 10:9-16. 2007
  7. ncbi A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail
    Peter N Morcos
    Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ, 07110, USA
    Eur J Clin Pharmacol 69:1939-49. 2013
  8. ncbi Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy
    Sebastian A Moreira
    Hoffmann La Roche Inc, Nutley, New Jersey, United Kingdom
    Pharmacotherapy 34:220-6. 2014
  9. pmc Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers
    Barbara J Brennan
    Hoffmann La Roche, Inc, Nutley, New Jersey, USA
    Antimicrob Agents Chemother 56:4729-37. 2012
  10. doi Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers
    Peter N Morcos
    Hoffmann La Roche Inc, Nutley, NJ, USA
    J Pharm Pharmacol 66:23-31. 2014

Collaborators

  • Jonathan Q Tran
  • Craig R Rayner
  • K Wang
  • Brian E Davies
  • Peter N Morcos
  • Sebastian A Moreira
  • Patrick F Smith
  • Mercidita T Navarro
  • Nuria Bech
  • Georgina Cirrincione-Dall
  • Amanda Quatkemeyer
  • Linda Chang
  • Rohit Kulkarni
  • Mylene Giraudon
  • Nancy Shulman
  • Rosa M Ballester-Sanchis

Detail Information

Publications12

  1. doi Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin
    Barbara J Brennan
    Pharma Research and Early Development, Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    Clin Pharmacokinet 52:805-13. 2013
    ..Danoprevir is a substrate of cytochrome P450 3A4, and the organic anion transporting polypeptides (OATP) 1B1 and 1B3...
  2. pmc Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity
    Barbara J Brennan
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Br J Clin Pharmacol 75:497-506. 2013
    ....
  3. doi Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study
    Barbara J Brennan
    Hoffmann La Roche Inc, Nutley, New Jersey 07110, USA
    Clin Ther 34:1883-91. 2012
    ..Because pegylated IFN (PEG-IFN) alfa-2a is administered subcutaneously, it is of interest to determine the proportion of the dose that is absorbed from the subcutaneous (SC) tissue and ultimately reaches systemic circulation...
  4. doi The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C
    B J Brennan
    Roche, Nutley, NJ, USA
    Aliment Pharmacol Ther 35:1209-20. 2012
    ..Amongst Caucasian, Hispanic and African Americans with genotype 1 hepatitis C virus (HCV), there is a wide variation in response to treatment with peginterferon alfa-2a (PEG-IFN alfa-2a) and ribavirin...
  5. ncbi Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease
    Barbara J Brennan
    Department of Pharmacy Practice, Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA
    J Am Pharm Assoc (2003) 44:604-10; quiz 610-1. 2004
    ..To review the pharmacology, safety, and efficacy data, as well as therapeutic use of eplerenone (Inspra-Pfizer) for management of cardiovascular and renal disease...
  6. ncbi Effect of age and gender on the pharmacokinetics of R667, a novel agent for the treatment of emphysema, in healthy volunteers
    B Brennan
    Hoffmann La Roche, Nutley, NJ, USA
    J Pharm Pharm Sci 10:9-16. 2007
    ..In conclusion these exposure differences are not considered clinically relevant, and no dose adjustment of R667 is required based on gender or age...
  7. ncbi A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail
    Peter N Morcos
    Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ, 07110, USA
    Eur J Clin Pharmacol 69:1939-49. 2013
    ....
  8. ncbi Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy
    Sebastian A Moreira
    Hoffmann La Roche Inc, Nutley, New Jersey, United Kingdom
    Pharmacotherapy 34:220-6. 2014
    ..To investigate the steady-state pharmacokinetics of methadone when coadministered with ritonavir-boosted danoprevir (DNVr)...
  9. pmc Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers
    Barbara J Brennan
    Hoffmann La Roche, Inc, Nutley, New Jersey, USA
    Antimicrob Agents Chemother 56:4729-37. 2012
    ..v. over 2 h twice daily for 5 days. These results support further exploration of i.v. oseltamivir as an influenza treatment option for patients unable to take oral medication...
  10. doi Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers
    Peter N Morcos
    Hoffmann La Roche Inc, Nutley, NJ, USA
    J Pharm Pharmacol 66:23-31. 2014
    ..To evaluate the effect of a low- and high-fat meal and co-administration of ranitidine or omeprazole on the pharmacokinetics of ritonavir-boosted danoprevir (DNVr)...
  11. doi Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study
    Georgina Cirrincione-Dall
    Hoffmann La Roche, Inc, Nutley, NJ, USA
    J Clin Pharmacol 52:1255-64. 2012
    ..There were no serious adverse events and no deaths. Combination therapy with oseltamivir and rimantadine at recommended dosages in adults had no discernible effect on the pharmacokinetics of either drug and raised no tolerability issues...
  12. ncbi Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men
    Barbara J Brennan
    Hoffmann La Roche, Nutley, New Jersey, USA
    J Clin Pharmacol 46:222-8. 2006
    ..R667 exposure was not affected by midazolam coadministration as compared with historical data. Based on the results of this study, no significant pharmacokinetic interaction should be anticipated between R667 and CYP3A4 substrates...